Immunomodulatory role of metalloproteinase ADAM17 in tumor development

Front Immunol. 2022 Nov 17:13:1059376. doi: 10.3389/fimmu.2022.1059376. eCollection 2022.

Abstract

ADAM17 is a member of the a disintegrin and metalloproteinase (ADAM) family of transmembrane proteases involved in the shedding of some cell membrane proteins and regulating various signaling pathways. More than 90 substrates are regulated by ADAM17, some of which are closely relevant to tumor formation and development. Besides, ADAM17 is also responsible for immune regulation and its substrate-mediated signal transduction. Recently, ADAM17 has been considered as a major target for the treatment of tumors and yet its immunomodulatory roles and mechanisms remain unclear. In this paper, we summarized the recent understanding of structure and several regulatory roles of ADAM17. Importantly, we highlighted the immunomodulatory roles of ADAM17 in tumor development, as well as small molecule inhibitors and monoclonal antibodies targeting ADAM17.

Keywords: ADAM17; immune response; inflammation; shedding activity; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM17 Protein
  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological*
  • Humans
  • Immunomodulation
  • Metalloproteases
  • Neoplasms*

Substances

  • Metalloproteases
  • Antineoplastic Agents, Immunological
  • Antibodies, Monoclonal
  • ADAM17 protein, human
  • ADAM17 Protein